

## Iressa (gefitinib) Prior Authorization Request Form Caterpillar Prescription Drug Benefit



Phone: 877-228-7909 Fax: 800-424-7640

**Instructions:** Please fill out all applicable sections completely and legibly. Attach any additional documentation that is important for the review (e.g., chart notes or lab data, to support the authorization request). Information contained in this form is Protected Health Information under HIPAA.

	URGENT			
MEMBER INFORMATION				
LAST NAME:	FIRST NAME:			
PHONE NUMBER:	DATE OF BIRTH:			
STREET ADDRESS:				
CITY:	STATE: ZIP CODE:			
PATIENT INSURANCE ID NUMBER:				
MALE FEMALE HEIGHT (IN/CM): WEIGI	HT (LB/KG): ALLERGIES:			

IF YOU ARE NOT THE PATIENT OR THE PRESCRIBER, YOU WILL NEED TO SUBMIT A PHI DISCLOSURE AUTHORIZATION FORM WITH THIS REQUEST WHICH CAN BE FOUND AT THE FOLLOWING LINK: <u>https://magellanrx.com/member/external/commercial/common/doc/en-us/phi\_disclosure\_authorization.pdf</u>

PRESCRIBER INFORMATION				
LAST NAME:	FIRST NAME:			
PRESCRIBER SPECIALTY:	EMAIL ADDRESS:			
NPI NUMBER:	DEA NUMBER:			
PHONE NUMBER:	FAX NUMBER:			
STREET ADDRESS:				
CITY:	STATE: ZIP CODE:			
REQUESTOR (if different than prescriber):	OFFICE CONTACT PERSON:			

MEDICATION OR MEDICAL DISPENSING INFORMATION					
MEDICATION NAME:					
DOSE/STRENGTH:	FREQUENCY:	LENGTH OF THERAPY/REFILLS:	QUANTITY:		
NEW THERAPY	RENEWAL	IF RENEWAL: DATE THERAPY	INITIATED:		
DURATION OF THERAPY (SPECIFIC DATES):					

Continued on next page.







## Iressa (gefitinib) Prior Authorization Request Form Caterpillar Prescription Drug Benefit



Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME:	MEMBER'S FIRST NAME:			
1. HAS THE PATIENT TRIED ANY OTHER	R MEDICATIONS FOR THIS CONDITION?	YES (if yes, complete below) NO		
MEDICATION/THERAPY (SPECIFY DRUG NAME AND DOSAGE):	<b>DURATION OF THERAPY</b> (SPECIFY DATES):	RESPONSE/REASON FOR FAILURE/ALLERGY:		
2. LIST DIAGNOSES:		ICD-10:		
<ul> <li>Non-small cell lung cancer</li> <li>Other DiagnosisICD-10 Control</li> </ul>				
<b>3. REQUIRED CLINICAL INFORMATION</b> PRIOR AUTHORIZATION.	PLEASE PROVIDE ALL RELEVANT CLINIC	AL INFORMATION TO SUPPORT A		
Clinical Information: Does the patient have locally advanced or metastatic non-small cell lung cancer (NSCLC)?  Yes  No Does the patient have an EGFR exon 19 deletion?*  Yes  No				
Does the patient have an EGFR exon 21 (L858R) substitution mutation?* □ Yes □ No *Please submit test confirmation.				
Has the patient received a prior trial of <u>standard</u> (i.e., NON-ADJUVANT) oral or parenteral chemotherapy for NSCLC (does not include patients with a history of prior surgery and/or radiotherapy, either with or without chemotherapy)? <ul> <li>Yes</li> <li>No</li> </ul>				
Will Iressa (gefitinib) be used as a first-line therapeutic agent?   Yes  No				
Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?				
<b>Please note:</b> Not all drugs/diagnosis are covered on all plans. This request may be denied unless all required information is received.				
<b>ATTESTATION:</b> I attest the information provided is true and accurate to the best of my knowledge. I understand that the Health Plan, insurer, Medical Group or its designees may perform a routine audit and request the medical information necessary to verify the accuracy of the information reported on this form.				
Prescriber Signature or Electronic I.D.		Date:		
<b>CONFIDENTIALITY NOTICE:</b> The documents according you are not the intended recipient, you are here	ompanying this transmission contain confidential by notified that any disclosure, copying, distribut have received this information in error, please no	health information that is legally privileged. If ion, or action taken in reliance on the contents		
FAX THIS FORM TO: 800-424-7640				
MAIL REQUESTS 1	<b>O:</b> Magellan Rx Management Prior Auth Attn: CP - 4201	orization Program		
	P.O. Box 64811 St. Paul, MN 55164-0811			



Mage